Read on to find out the winners of our Dealmaker Poll 2024.

The two large listings are adding to a sense of optimism, in particular in India and Hong Kong, with Taiwan enjoying a record year so far; and occurred before the US Fed cut rates.

The Chinese vehicle chip firm made its debut on the HKEX amid market instability, and saw a slump in its share price.

ECM and M&A activity plunged by 66.2% and 21.6% respectively, however DCM demonstrated resilience, dropping slightly by 1.8%.

The rationale behind all the winners in mainland China, Hong Kong, South Korea and Taiwan.

Will the Middle East provide an opportunity for China to push forward the internationalisation goal for its currency? Experts say it’s happening, but all too slowly.

FA recently asked experts on their experience working on the first listing under HKEX’s newly introduced Chapter 18C for tech firms in the new economy.

An acquisition in Hong Kong by the New Frontier Group, an IPO by Sunho Biologics on the HKEX and a $1.5bn investment into Singapore by AstraZeneca, are signs that investments in next generation cancer treatments are increasing in the region.

A postponement of the US Federal Reserve interest rate cuts could see some defensive plays by investors, such as range-bound trading.

While a smaller size signalled a yet-to-rebound Hong Kong stock market, Lianlian is the first fintech firm to be approved by the CSRC since its registration-based new rules.